Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private-label omeprazole gets final OK

This article was originally published in The Tan Sheet

Executive Summary

FDA grants final approval to Israel-based Dexcel Pharma Technologies' 20 mg omeprazole delayed-release tablets, Perrigo announces Dec. 10. Perrigo will be the exclusive marketer and distributor of the store brand Prilosec OTC, and plans to begin distribution of the product during the first quarter of 2008, the Allegan, Mich.-private labeler states. The firm expects the generic omeprazole product to contribute $150 mil. to $200 mil. in sales in 2008, according to a release. The upcoming launch of the omeprazole product, which Perrigo CEO Joseph Papa expects to be the "largest product in Perrigo's 120-year history," comes after the private-labeler's November announcement of a settlement to litigation between Dexcel Pharma and AstraZeneca, the manufacturer of Prilosec OTC (1"The Tan Sheet" Nov. 5, 2007, p. 10). The settlement resolves a legal dispute that began when Dexcel filed a new drug application in April 2006 with a Paragraph IV certification asserting AstraZeneca's Prilosec OTC patents were invalid and would not be infringed by its generic version of the drug (2"The Tan Sheet" June 12, 2006, p. 5)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel